Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI)

Trial Profile

Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Thalidomide (Primary) ; Vorinostat (Primary) ; Stem cell therapies
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms Myeloma XI+; Myeloma-XI; UK NCRI Myeloma XI; Ukmrc Myeloma XI
  • Most Recent Events

    • 12 Dec 2023 Results assessing The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Results (n=4358)assessing the impact of len on SPM development when used at induction and maintenance, profiling SPM type and incidence, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Results (from two studies OPTIMUM/MUKnine and Myeloma XI ) assessing outcomes for OPTIMUM patients until end of consolidation therapy and contextualise results with outcomes of UHiR MM patients treated in the Myeloma XI presented at the 64th American Society of Hematology Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top